— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage —
— BRINSUPRI 10...
NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (Nasdaq: KLTO), announces that it signed a binding agreement to initiate manufacturing and development...
Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous...
MISSION, Kan., Aug. 11, 2025 /PRNewswire/ -- (Family Features) Staying in shape goes beyond physical fitness – keeping your brain health top of mind is...
Costco Members Can Now Enjoy Lifeway's Probiotic, Protein-Packed Kefir in Convenient 8oz Multi-Pack Boxes
MORTON GROVE, Ill., Aug. 11, 2025 /PRNewswire/ -- Lifeway Foods, Inc....
STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events.
– Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant –
BRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) underlying 48,200 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
JERUSALEM, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended June 30, 2025.
MORTON GROVE, Ill., Aug. 8, 2025 /PRNewswire/ -- Lifeway Foods, Inc. (NASDAQ: LWAY), a leading U.S. supplier of kefir and fermented probiotic products, is...
Guests can enjoy Chick-fil-A's first-ever seasonal soda, a bold new sandwich and the crunch of new chips
ATLANTA, Aug. 8, 2025 /PRNewswire/ -- Launching August...
MINNEAPOLIS and ST. PAUL, Minn., Aug. 08, 2025 (GLOBE NEWSWIRE) -- As global demand for protein continues to rise, Minnesota-based MBOLD (an initiative of the GREATER MSP Partnership) and the Agricultural Utilization Research Institute (AURI) have launched the Protein Navigator, a new service designed to help protein-focused companies explore, enter and grow within Minnesota’s dynamic food and agriculture ecosystem.